ReviewAdvanced biomedical research2025
Competing Endogenous RNA Networks Reveal Long Non-coding RNAs as Potential Prognostic Biomarkers in Gastric Cancer: A Systematic Review and Meta-Analysis.
Review in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) represents a global healthcare challenge. Recently, many competing endogenous RNA (ceRNA) network studies have elucidated critical long noncoding RNAs (lncRNAs) as potential prognostic biomarkers in GC. Since there is no systematic review and meta-analysis regarding the lncRNAs as ceRNA in GC, we propose the current study. Materials and Methods: The Web of Science, Embase, PubMed, Scopus, ProQuest, and Google Scholar databases were searched to collect eligible ceRNA network studies in which lncRNAs were reported as prognostic biomarkers until 20 Results: Totally, 56 studies were included in the systematic review. Based on these studies, the association of 350 unique lncRNAs with overall survival of GC patients were evaluated. 28 studies were eligible for meta-analysis. Four lncRNAs including Conclusion: Our meta-analysis demonstrated potential application of lncRNA Registration: The review protocol was registered on The International Prospective Register of Systematic Reviews (PROSPERO) (CRD42022360864).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.